<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://ajpendo.physiology.org">
<title>AJP: Endocrinology and Metabolism recent issues</title>
<link>http://ajpendo.physiology.org</link>
<description>AJP: Endocrinology and Metabolism RSS feed -- recent issues</description>
<prism:eIssn>1522-1555</prism:eIssn>
<prism:publicationName>AJP: Endocrinology and Metabolism</prism:publicationName>
<prism:issn>0193-1849</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E531?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E536?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E545?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E553?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E559?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E569?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E575?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E586?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E595?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E605?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E613?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E618?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E626?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E637?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E648?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E658?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E665?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E672?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E678?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E686?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E692?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E698?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E705?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E714?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E719?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/full/295/3/E727?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/full/295/3/E729?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/full/295/2/E225?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E227?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E238?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E242?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E254?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E262?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E269?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E278?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E287?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E297?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E305?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E313?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E323?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E331?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E339?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E350?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E356?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E368?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E380?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E385?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E393?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E401?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E407?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E413?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E420?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E428?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E436?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E446?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E456?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E463?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E477?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E491?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E497?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E505?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E514?rss=1" />
  <rdf:li rdf:resource="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E519?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://ajpendo.physiology.org/icons/banner/title.gif" />
</channel>

<image rdf:about="http://ajpendo.physiology.org/icons/banner/title.gif">
<title>AJP: Endocrinology and Metabolism</title>
<url>http://ajpendo.physiology.org/icons/banner/title.gif</url>
<link>http://ajpendo.physiology.org</link>
</image>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E531?rss=1">
<title><![CDATA[Why are we shaped differently, and why does it matter?]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E531?rss=1</link>
<description><![CDATA[ 
<P>Body fat distribution is an important predictor of metabolic abnormalities in obese humans. Dysregulation of free fatty acid (FFA) release, especially from upper body subcutaneous adipose tissue, appears to contribute substantially to these metabolic disturbances. Why different individuals preferentially store fat in upper vs. lower body subcutaneous fat or subcutaneous vs. visceral fat is not completely understood. Current evidence suggests that defects in regional lipolysis are not the cause of net fat retention in larger fat depots. Regional variations in the storage of fatty acids, both meal derived and direct reuptake, and storage of circulating FFAs that may help to explain why some depots expand at the expense of others have been reported. We review the quantitative data on regional lipolysis, meal, and FFA storage in adults to provide an overview of fat balance differences in adults with different fat distribution patterns.</P>
]]></description>
<dc:creator><![CDATA[Santosa, S., Jensen, M. D.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90357.2008</dc:identifier>
<dc:title><![CDATA[Why are we shaped differently, and why does it matter?]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E535</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E531</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E536?rss=1">
<title><![CDATA[Phosphoinositides in insulin action on GLUT4 dynamics: not just PtdIns(3,4,5)P3]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E536?rss=1</link>
<description><![CDATA[ 
<P>Accumulated evidence over the last several years indicates that insulin regulates multiple steps in the overall translocation of GLUT4 vesicles to the fat/muscle cell surface, including formation of an intracellular storage pool of GLUT4 vesicles, its movement to the proximity of the cell surface, and the subsequent docking/fusion with the plasma membrane. Insulin-stimulated formation of phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P<SUB>3</SUB>; and in some cases, of its catabolite PtdIns(3,4)P<SUB>2</SUB>] plays a pivotal role in this process. PtdIns(3,4,5)P<SUB>3</SUB> is synthesized by the activated wortmannin-sensitive class IA phosphoinositide (PI) 3-kinase and controls the rate-limiting cell surface terminal stages of the GLUT4 journey. However, recent research is consistent with the conclusion that signals by each of the remaining five PIs, i.e., PtdIns(3)P, PtdIns(4)P, PtdIns(5)P, PtdIns(3,5)P<SUB>2</SUB>, and PtdIns(4,5)P<SUB>2</SUB>, may act in concert with that of PtdIns(3,4,5)P<SUB>3</SUB> in integrating the insulin receptor-issued signals with GLUT4 surface translocation and glucose transport activation. This review summarizes the experimental evidence supporting the complementary function of these PIs in insulin responsiveness of fat and muscle cells, with particular reference to mechanistic insights and functional significance in the regulation of overall GLUT4 vesicle dynamics.</P>
]]></description>
<dc:creator><![CDATA[Shisheva, A.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90353.2008</dc:identifier>
<dc:title><![CDATA[Phosphoinositides in insulin action on GLUT4 dynamics: not just PtdIns(3,4,5)P3]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E544</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E536</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E545?rss=1">
<title><![CDATA[Influence of AMP-activated protein kinase and calcineurin on metabolic networks in skeletal muscle]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E545?rss=1</link>
<description><![CDATA[ 
<P>Skeletal muscle fibers differ considerably in their metabolic and physiological properties. Skeletal muscle displays a high degree of metabolic flexibility, which allows the myofibers to adapt to various physiological demands by shifting energy substrate utilization. Transcriptional events play a pivotal role in the metabolic adaptations of skeletal muscle. The expression of genes essential for skeletal muscle glucose and lipid metabolism is tightly coordinated in support of a shift in substrate utilization. AMP-activated protein kinase (AMPK) and calcineurin (a calcium-regulated serine/threonine protein phosphatase) regulate skeletal muscle metabolic gene expression programs in response to changes in the energy status and levels of neuronal input, respectively. AMPK and calcineurin activate transcriptional regulators such as peroxisome proliferator-activated receptor- coactivator-1 and myocyte enhancer factor as well as increase skeletal muscle oxidative capacity and mitochondrial gene expression. Activation of either the AMPK or calcineurin pathway can also enhance the glycogen storage capacity and insulin sensitivity in skeletal muscle. Characterization of pathways governing skeletal muscle metabolism offers insight into physiological and pharmacological strategies to prevent or ameliorate peripheral insulin resistance associated with metabolic disorders such as type 2 diabetes.</P>
]]></description>
<dc:creator><![CDATA[Long, Y. C., Zierath, J. R.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90259.2008</dc:identifier>
<dc:title><![CDATA[Influence of AMP-activated protein kinase and calcineurin on metabolic networks in skeletal muscle]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E552</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E545</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E553?rss=1">
<title><![CDATA[Frontiers: Skeletal muscle sodium pump regulation: a translocation paradigm]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E553?rss=1</link>
<description><![CDATA[ 
<P>The skeletal muscle sodium pump plays a major role in the removal of K<SUP>+</SUP> ions from the circulation postprandial, or after a physical activity bout, thereby preventing the development of hyperkalemia and fatigue. Insulin and muscle contractions stimulate Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase activity in skeletal muscle, at least partially via translocation of sodium pump units to the plasma membrane from intracellular stores. The molecular mechanism of this phenomenon is poorly understood. Due to the contradictory reports in the literature, the very existence of the translocation of Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase to the skeletal muscle cell surface is questionable. This review summarizes more than 30 years work on the skeletal muscle sodium pump translocation paradigm. Furthermore, the methodological caveats of major approaches to study the sodium pump translocation in skeletal muscle are discussed. An understanding of the molecular regulation of Na<SUP>+</SUP>-K<SUP>+</SUP>-ATPase in skeletal muscle will have important clinical implications for the understanding of the development of complications associated with the metabolic syndrome, such as cardiovascular diseases or increased muscle fatigue in diabetic patients.</P>
]]></description>
<dc:creator><![CDATA[Benziane, B., Chibalin, A. V.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90261.2008</dc:identifier>
<dc:title><![CDATA[Frontiers: Skeletal muscle sodium pump regulation: a translocation paradigm]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E558</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E553</prism:startingPage>
<prism:section>PERSPECTIVES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E559?rss=1">
<title><![CDATA[Estrous cycle variation of TRPV1-mediated cross-organ sensitization between uterus and NMDA-dependent pelvic-urethra reflex activity]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E559?rss=1</link>
<description><![CDATA[ 
<P>Cross-organ sensitization between the uterus and the lower urinary tract (LUT) underlies the high concurrence of pelvic pain syndrome and LUT dysfunctions, and yet the role of gonadal steroids is still unknown. We tested the hypothesis that cross-organ sensitization on pelvic-urethra reflex activity caused by uterine capsaicin instillation is estrous cycle dependent. When compared with the baseline reflex activity (1.00 &plusmn; 0.00 spikes/stimulation), uterine capsaicin instillation significantly increased reflex activity (45.42 &plusmn; 9.13 spikes/stimulation, <I>P</I> &lt; 0.01, <I>n</I> = 7) that was corroborated by an increase in phosphorylated NMDA NR2B (<I>P</I> &lt; 0.05, <I>n</I> = 4) but not NR2A subunit (<I>P</I> &gt; 0.05, <I>n</I> = 4) expression. Both intrauterine pretreatment with capsazepine (5.02 &plusmn; 2.11 spikes/stimulation, <I>P</I> &lt; 0.01, <I>n</I> = 7) and an intrathecal injection of AP5 (3.21 &plusmn; 0.83 spikes/stimulation, <I>P</I> &lt; 0.01, <I>n</I> = 7) abolished the capsaicin-induced cross-organ sensitization and the increment in the phosphorylated NR2B level (<I>P</I> &lt; 0.05, <I>n</I> = 4). The degrees of the cross-organ sensitization increased in a dose-dependent manner with the concentration of instilled capsaicin from 100 to 300 &micro;M in both the proestrus and metestrus stages, whereas they weakened when the concentrations were higher than 1,000 &micro;M. Moreover, the cross-organ sensitization caused by the uterine capsaicin instillation increased significantly in the rats during the proestrus stage when compared with the metestrus stage (<I>P</I> &lt; 0.01, <I>n</I> = 7). These results suggest that estrogen levels might modulate the cross-organ sensitization between the uterus and the urethra and underlie the high concurrence of pelvic pain syndrome and LUT dysfunctions.</P>
]]></description>
<dc:creator><![CDATA[Peng, H.-Y., Huang, P.-C., Liao, J.-M., Tung, K.-C., Lee, S.-D., Cheng, C.-L., Shyu, J.-C., Lai, C.-Y., Chen, G.-D., Lin, T.-B.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90289.2008</dc:identifier>
<dc:title><![CDATA[Estrous cycle variation of TRPV1-mediated cross-organ sensitization between uterus and NMDA-dependent pelvic-urethra reflex activity]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E568</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E559</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E569?rss=1">
<title><![CDATA[Measurement of pulsatile insulin secretion in the rat: direct sampling from the hepatic portal vein]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E569?rss=1</link>
<description><![CDATA[ 
<P>It has previously been shown that insulin is secreted in discrete secretory bursts by sampling directly from the portal vein in the dog and humans. Deficient pulsatile insulin secretion is the basis for impaired insulin secretion in type 2 diabetes. However, while novel genetically modified disease models of diabetes are being developed in rodents, no validated method for quantifying pulsatile insulin secretion has been established for rodents. To address this we <I>1</I>) developed a novel rat model with chronically implanted portal vein catheters, <I>2</I>) established the parameters to permit deconvolution of portal vein insulin concentrations profiles to measure insulin secretion and resolve its pulsatile components, and <I>3</I>) measured total and pulsatile insulin secretion compared with that in the dog, the species in which this sampling and deconvolution approach was validated for quantifying pulsatile insulin secretion. In rats, portal vein catheter patency and function were maintained for periods up to 2&ndash;3 wk with no postoperative complications such as catheter tract infection. Rat portal vein insulin concentration profiles in the fasting state revealed distinct insulin oscillations with a periodicity of ~5 min and an amplitude of up to 600 pmol/l, which was remarkably similar to that in the dogs and in humans. Deconvolution analysis of portal vein insulin concentrations revealed that the majority of insulin (~70%) in the rat is secreted in distinct insulin pulses occurring at ~5-min intervals. This model therefore permits direct accurate measurments of pulsatile insulin secretion in a relatively inexpensive animal. With increased introduction of genetically modified rat models will be an important tool in elucidating the underlying mechanisms of impaired pulsatile insulin secretion in diabetes.</P>
]]></description>
<dc:creator><![CDATA[Matveyenko, A. V., Veldhuis, J. D., Butler, P. C.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90335.2008</dc:identifier>
<dc:title><![CDATA[Measurement of pulsatile insulin secretion in the rat: direct sampling from the hepatic portal vein]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E574</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E569</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E575?rss=1">
<title><![CDATA[Amplification of pulsatile glucagon counterregulation by switch-off of {alpha}-cell-suppressing signals in streptozotocin-treated rats]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E575?rss=1</link>
<description><![CDATA[ 
<P>Glucagon counterregulation (GCR) is a key protection against hypoglycemia that is compromised in diabetes via an unknown mechanism. To test the hypothesis that -cell-inhibiting signals that are switched off during hypoglycemia amplify GCR, we studied streptozotocin (STZ)-treated male Wistar rats and estimated the effect on GCR of intrapancreatic infusion and termination during hypoglycemia of saline, insulin, and somatostatin. Times 10 min before and 45 min after the switch-off were analyzed. Insulin and somatostatin, but not saline, switch-off significantly increased the glucagon levels (<I>P</I> = 0.03), and the fold increases relative to baseline were significantly higher (<I>P</I> &lt; 0.05) in the insulin and somatostatin groups vs. the saline group. The peak concentrations were also higher in the insulin (368 pg/ml) and somatostatin (228 pg/ml) groups vs. the saline (114 pg/ml) group (<I>P</I> &lt; 0.05). GCR was pulsatile in most animals, indicating a feedback regulation. After the switch-off, the number of secretory events and the total pulsatile production were lower in the saline group vs. the insulin and somatostatin groups (<I>P</I> &lt; 0.05), indicating enhancement of glucagon pulsatile activity by insulin and somatostatin compared with saline. Network modeling analysis demonstrates that reciprocal interactions between - and -cells can explain the amplification by interpreting the GCR as a rebound response to the switch-off. The model justifies experimental designs to further study the intrapancreatic network in relation to the switch-off phenomenon. The results of this proof-of-concept interdisciplinary study support the hypothesis that GCR develops as a rebound pulsatile response of the intrapancreatic endocrine feedback network to switch-off of -cell-inhibiting islet signals.</P>
]]></description>
<dc:creator><![CDATA[Farhy, L. S., Du, Z., Zeng, Q., Veldhuis, P. P., Johnson, M. L., Brayman, K. L., McCall, A. L.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90372.2008</dc:identifier>
<dc:title><![CDATA[Amplification of pulsatile glucagon counterregulation by switch-off of {alpha}-cell-suppressing signals in streptozotocin-treated rats]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E585</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E575</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E586?rss=1">
<title><![CDATA[Voluntary exercise improves insulin sensitivity and adipose tissue inflammation in diet-induced obese mice]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E586?rss=1</link>
<description><![CDATA[ 
<P>Exercise promotes weight loss and improves insulin sensitivity. However, the molecular mechanisms mediating its beneficial effects are not fully understood. Obesity correlates with increased production of inflammatory cytokines, which in turn, contributes to systemic insulin resistance. To test the hypothesis that exercise mitigates this inflammatory response, thereby improving insulin sensitivity, we developed a model of voluntary exercise in mice made obese by feeding of a high fat/high sucrose diet (HFD). Over four wk, mice fed chow gained 2.3 &plusmn; 0.3 g, while HFD mice gained 6.8 &plusmn; 0.5 g. After 4 wk, mice were subdivided into four groups: chow-no exercise, chow-exercise, HFD-no exercise, HFD-exercise and monitored for an additional 6 wk. Chow-no exercise and HFD-no exercise mice gained an additional 1.2 &plusmn; 0.3 g and 3.3 &plusmn; 0.5 g respectively. Exercising mice had higher food consumption, but did not gain additional weight. As expected, GTT and ITT showed impaired glucose tolerance and insulin resistance in HFD-no exercise mice. However, glucose tolerance improved significantly and insulin sensitivity was completely normalized in HFD-exercise animals. Furthermore, expression of TNF-, MCP-1, PAI-1 and IKK&beta; was increased in adipose tissue from HFD mice compared with chow mice, whereas exercise reversed the increased expression of these inflammatory cytokines. In contrast, expression of these cytokines in liver was unchanged among the four groups. These results suggest that exercise partially reduces adiposity, reverses insulin resistance and decreases adipose tissue inflammation in diet-induced obese mice, despite continued consumption of HFD.</P>
]]></description>
<dc:creator><![CDATA[Bradley, R. L., Jeon, J. Y., Liu, F.-F., Maratos-Flier, E.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00309.2007</dc:identifier>
<dc:title><![CDATA[Voluntary exercise improves insulin sensitivity and adipose tissue inflammation in diet-induced obese mice]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E594</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E586</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E595?rss=1">
<title><![CDATA[Disassociation between the effects of amino acids and insulin on signaling, ubiquitin ligases, and protein turnover in human muscle]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E595?rss=1</link>
<description><![CDATA[ 
<P>We determined the effects of intravenous infusion of amino acids (AA) at serum insulin of 5, 30, 72, and 167 mU/l on anabolic signaling, expression of ubiquitin-proteasome components, and protein turnover in muscles of healthy young men. Tripling AA availability at 5 mU/l insulin doubled incorporation of [1-<SUP>13</SUP>C]leucine [i.e., muscle protein synthesis (MPS), <I>P</I> &lt; 0.01] without affecting the rate of leg protein breakdown (LPB; appearance of d<SUB>5</SUB>-phenylalanine). While keeping AA availability constant, increasing insulin to 30 mU/l halved LPB (<I>P</I> &lt; 0.05) without further inhibition at higher doses, whereas rates of MPS were identical to that at 5 mU/l insulin. The phosphorylation of PKB Ser<SUP>473</SUP> and p70<SUP>S6k</SUP> Thr<SUP>389</SUP> increased concomitantly with insulin, but whereas raising insulin to 30 mU/l increased the phosphorylation of mTOR Ser<SUP>2448</SUP>, 4E-BP1 Thr<SUP>37/46</SUP>, or GSK3&beta; Ser<SUP>9</SUP> and decreased that of eEF2 Thr<SUP>56</SUP>, higher insulin doses to 72 and 167 mU/l did not augment these latter responses. MAFbx and proteasome C2 subunit proteins declined as insulin increased, with MuRF-1 expression largely unchanged. Thus increasing AA and insulin availability causes changes in anabolic signaling and amounts of enzymes of the ubiquitin-proteasome pathway, which cannot be easily reconciled with observed effects on MPS or LPB.</P>
]]></description>
<dc:creator><![CDATA[Greenhaff, P. L., Karagounis, L. G., Peirce, N., Simpson, E. J., Hazell, M., Layfield, R., Wackerhage, H., Smith, K., Atherton, P., Selby, A., Rennie, M. J.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90411.2008</dc:identifier>
<dc:title><![CDATA[Disassociation between the effects of amino acids and insulin on signaling, ubiquitin ligases, and protein turnover in human muscle]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E604</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E595</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E605?rss=1">
<title><![CDATA[Altered response to metabolic challenges in mice with genetically targeted deletions of galanin-like peptide]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E605?rss=1</link>
<description><![CDATA[ 
<P>Galanin-like peptide (GALP) is expressed in the arcuate nucleus and is implicated in the neuroendocrine regulation of metabolism and reproduction. To investigate the physiological significance of GALP, we generated and characterized a strain of mice with a genetically targeted deletion in the <I>GALP</I> gene [GALP knockout (KO) mice]. We report that GALP KO mice have a subtle, but notable, metabolic phenotype that becomes apparent during adaptation to changes in nutrition. GALP KO mice are indistinguishable from wild-type (WT) controls in virtually all aspects of growth, sexual development, body weight, food and water consumption, and motor behaviors, when they are allowed unlimited access to standard rodent chow. However, GALP KO mice have an altered response to changes in diet. <I>1</I>) Male GALP KO mice consumed less food during refeeding after a fast than WT controls (<I>P</I> &lt; 0.01). <I>2</I>) GALP KO mice of both sexes gained less weight on a high-fat diet than WT controls (<I>P</I> &lt; 0.01), despite both genotypes having consumed equal amounts of food. We conclude that although GALP signaling may not be essential for the maintenance of energy homeostasis under steady-state nutritional conditions, GALP may play a role in readjusting energy balance under changing nutritional circumstances.</P>
]]></description>
<dc:creator><![CDATA[Dungan Lemko, H. M., Clifton, D. K., Steiner, R. A., Fraley, G. S.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90425.2008</dc:identifier>
<dc:title><![CDATA[Altered response to metabolic challenges in mice with genetically targeted deletions of galanin-like peptide]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E612</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E605</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E613?rss=1">
<title><![CDATA[Hyperglycemia prevents the suppressive effect of hyperinsulinemia on plasma adiponectin levels in healthy humans]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E613?rss=1</link>
<description><![CDATA[ 
<P>Adiponectin is a fat-derived hormone with insulin-sensitizing properties. In patients with type 2 diabetes plasma adiponectin levels are decreased. Since these patients are characterized by high plasma insulin and glucose concentrations, hyperinsulinemia and hyperglycemia could be responsible for the downregulation of adiponectin. Insulin decreases adiponectin levels in humans. The effect of hyperglycemia is unknown. To determine the selective effects of insulin, glucose, or their combination on plasma adiponectin, clamps were performed in six healthy males on four occasions in a crossover design: <I>1</I>) lower insulinemic-euglycemic clamp (100 pmol/l insulin, 5 mmol/l glucose) (reference clamp); <I>2</I>) hyperinsulinemic-euglycemic clamp (400 pmol/l insulin, 5 mmol/l glucose); <I>3</I>) lower insulinemic-hyperglycemic clamp (100 pmol/l insulin, 12 mmol/l glucose); and <I>4</I>) hyperinsulinemic-hyperglycemic clamp (400 pmol/l insulin, 12 mmol/l glucose). Adiponectin concentrations and high-molecular-weight (HMW)-to-total adiponectin ratio were measured at the start and end of the 6-h clamps. After the 6-h study period, total plasma adiponectin levels were significantly (<I>P</I> = 0.045) decreased by 0.63 &micro;g/ml in the lower insulinemic-euglycemic clamp (<I>clamp 1</I>). In both euglycemic groups (<I>clamps 1</I> and <I>2</I>) adiponectin concentrations significantly declined (<I>P</I> = 0.016) over time by 0.56 &micro;g/ml, whereas there was no change in both hyperglycemic groups (<I>clamps 3</I> and <I>4</I>) (<I>P</I> = 0.420). In none of the clamps did the ratio of HMW to total adiponectin change. We conclude that insulin suppresses plasma adiponectin levels already at a plasma insulin concentration of 100 pmol/l. Hyperglycemia prevents the suppressive effect of insulin. This suggests that, in contrast to glucose, insulin could be involved in the downregulation of plasma adiponectin in insulin-resistant patients.</P>
]]></description>
<dc:creator><![CDATA[Blumer, R. M. E., van der Crabben, S. N., Stegenga, M. E., Tanck, M. W., Ackermans, M. T., Endert, E., van der Poll, T., Sauerwein, H. P.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90288.2008</dc:identifier>
<dc:title><![CDATA[Hyperglycemia prevents the suppressive effect of hyperinsulinemia on plasma adiponectin levels in healthy humans]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E617</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E613</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E618?rss=1">
<title><![CDATA[Effects of oral carbohydrate on autonomic nervous system counterregulatory responses during hyperinsulinemic hypoglycemia and euglycemia]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E618?rss=1</link>
<description><![CDATA[ 
<P>The effects of oral carbohydrate on modulating counterregulatory responses in humans remain undecided. This study's specific aim was to determine the effects of oral carbohydrate on autonomic nervous system (ANS) and neuroendocrine responses during hyperinsulinemic hypoglycemia and euglycemia. Nineteen healthy volunteers were studied during paired, single blind experiments. Nine subjects underwent two-step glucose clamps consisting of 60 min of euglycemia (5.0 mmol/l) followed by either 15 g of oral carbohydrate (cal) as orange juice or a noncaloric control (nocal) and subsequent 90 min of clamped hypoglycemia (2.9 mmol/l). Ten other subjects underwent two randomized 150-min hyperinsulinemic-euglycemic clamps with cal or nocal control administered at 60 min. Oral carbohydrate initially blunted (<I>P</I> &lt; 0.05) epinephrine, norepinephrine, cortisol, glucagon, pancreatic polypeptide, muscle sympathetic nerve activity (MSNA), symptom, and systolic blood pressure responses during hypoglycemia. However, by the end of 90 min of hypoglycemia, plasma epinephrine and norepinephrine responses had rebounded and were increased (<I>P</I> &lt; 0.05) compared with control. MSNA and cortisol levels remained suppressed during hypoglycemia (<I>P</I> &lt; 0.05) after cal, whereas pancreatic polypeptide, glucagon, symptom, and blood pressure responses increased similar to control following initial suppression. Oral carbohydrate had no effects on neuroendocrine or ANS responses during hyperinsulinemic euglycemia. These results demonstrate that oral carbohydrate can have differential effects on the time course of ANS and neuroendocrine responses during hypoglycemia. We conclude that gastro-splanchnic-portal sensing of an amount of carbohydrate recommended for use in clinical practice for correction of hypoglycemia can have widespread and significant effects on central nervous system mediated counterregulatory responses in healthy humans.</P>
]]></description>
<dc:creator><![CDATA[Ertl, A. C., Mann, S., Richardson, A., Briscoe, V. J., Blair, H. B., Tate, D. B., Davis, S. N.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90470.2008</dc:identifier>
<dc:title><![CDATA[Effects of oral carbohydrate on autonomic nervous system counterregulatory responses during hyperinsulinemic hypoglycemia and euglycemia]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E625</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E618</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E626?rss=1">
<title><![CDATA[Maternal protein restriction during early lactation induces GLUT4 translocation and mTOR/Akt activation in adipocytes of adult rats]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E626?rss=1</link>
<description><![CDATA[ 
<P>Epidemiological and experimental studies have demonstrated that early postnatal nutrition has been associated with long-term effects on glucose homeostasis in adulthood. Recently, our group demonstrated that undernutrition during early lactation affects the expression and activation of key proteins of the insulin signaling cascade in rat skeletal muscle during postnatal development. To elucidate the molecular mechanisms by which undernutrition during early life leads to changes in insulin sensitivity in peripheral tissues, we investigated the insulin signaling in adipose tissue. Adipocytes were isolated from epididymal fat pads of adult male rats that were the offspring of dams fed either a normal or a protein-free diet during the first 10 days of lactation. The cells were incubated with 100 nM insulin before the assays for immunoblotting analysis, 2-deoxyglucose uptake, immunocytochemistry for GLUT4, and/or actin filaments. Following insulin stimulation, adipocytes isolated from undernourished rats presented reduced tyrosine phosphorylation of IR and IRS-1 and increased basal phosphorylation of IRS-2, Akt, and mTOR compared with controls. Basal glucose uptake was increased in adipocytes from the undernourished group, and the treatment with LY294002 induced only a partial inhibition both in basal and in insulin-stimulated glucose uptake, suggesting an involvement of phosphoinositide 3-kinase activity. These alterations were accompanied by higher GLUT4 content in the plasma membrane and alterations in the actin cytoskeleton dynamics. These data suggest that early postnatal undernutrition impairs insulin sensitivity in adulthood by promoting changes in critical steps of insulin signaling in adipose tissue, which may contribute to permanent changes in glucose homeostasis.</P>
]]></description>
<dc:creator><![CDATA[Garcia-Souza, E. P., da Silva, S. V., Felix, G. B., Rodrigues, A. L., de Freitas, M. S., Moura, A. S., Barja-Fidalgo, C.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00439.2007</dc:identifier>
<dc:title><![CDATA[Maternal protein restriction during early lactation induces GLUT4 translocation and mTOR/Akt activation in adipocytes of adult rats]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E636</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E626</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E637?rss=1">
<title><![CDATA[Role of wild-type estrogen receptor-{beta} in mitochondrial cytoprotection of cultured normal male and female human lens epithelial cells]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E637?rss=1</link>
<description><![CDATA[ 
<P>The influence of sexual category as a modifier of cellular function is underinvestigated. Whether sex differences affect estrogen-mediated mitochondrial cytoprotection was determined using cell cultures of normal human lens epithelia (nHLE) from postmortem male and female donors. Experimental indicators assessed included differences in estrogen receptor-&beta; (ER&beta;) isoform expression, receptor localization in mitochondria, and estrogen-mediated prevention of loss of mitochondrial membrane potential using the potentiometric fluorescent compound JC-1 after nHLE were exposed to peroxide. The impact of wild-type ER&beta; (wtER&beta;1) was also assessed using wtER&beta;1 siRNA to suppress expression. A triple-primer PCR assay was employed to determine the proportional distribution of the receptor isoforms (wtER&beta;1, -&beta;2, and -&beta;5) from the total ER&beta; message pool in male and female cell cultures. Irrespective of sex, nHLE express wtER&beta;1 and the ER&beta;2 and ER&beta;5 splice variants in similar ratios. Confocal microscopy and immunofluorescence revealed localization of the wild-type receptor in peripheral mitochondrial arrays and perinuclear mitochondria as well as nuclear staining in both cell populations. The ER&beta;2 and ER&beta;5 isoforms were distributed primarily in the nucleus and cytosol, respectively; no association with the mitochondria was detected. Both male and female nHLE treated with E<SUB>2</SUB> (1 &micro;M) displayed similar levels of protection against peroxide-induced oxidative stress. In conjunction with acute oxidative insult, RNA suppression of wtER&beta;1 elicited the collapse of mitochondrial membrane potential and markedly diminished the otherwise protective effects of E<SUB>2</SUB>. Thus, whereas the estrogen-mediated prevention of mitochondrial membrane permeability transition is sex independent, the mechanism of estrogen-induced mitochondrial cytoprotection is wtER&beta;1 dependent.</P>
]]></description>
<dc:creator><![CDATA[Flynn, J. M., Dimitrijevich, S. D., Younes, M., Skliris, G., Murphy, L. C., Cammarata, P. R.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90407.2008</dc:identifier>
<dc:title><![CDATA[Role of wild-type estrogen receptor-{beta} in mitochondrial cytoprotection of cultured normal male and female human lens epithelial cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E647</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E637</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E648?rss=1">
<title><![CDATA[Pax6 and Pdx1 are required for production of glucose-dependent insulinotropic polypeptide in proglucagon-expressing L cells]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E648?rss=1</link>
<description><![CDATA[ 
<P>Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are incretin hormones that play important roles in maintaining glucose homeostasis and are being actively pursued as novel therapeutic agents for diabetes. GIP is produced by dispersed enteroendocrine cells and interestingly at times is coexpressed with GLP-1. We sought to determine the factors that selectively define GIP- vs. GLP-1-expressing cells. We performed comparative immunostaining of Pax6 and Pdx1 in GIP- and GLP-1-secreting cells. We investigated whether Pax6 and Pdx1 activate the human GIP promoter in control IEC-6 cells and GIP-expressing STC-1 cells. EMSA was performed to assess the binding of these transcription factors to the GIP promoter. Pax6 and Pdx1 consistently colocalized in GIP-immunoreactive cells. Cells that coexpress GIP and GLP-1 were Pax6 and Pdx1 positive, whereas cells expressing only GLP-1 were Pax6 positive but did not express Pdx1. GIP promoter activity was enhanced in IEC-6 cells by exogenous Pax6 or Pdx1 and diminished in STC-1 cells by inhibition of endogenous Pax6 or Pdx1 by dominant-negative forms. Promoter truncation analysis revealed a major loss of promoter activity when the sequence between &ndash;184 to &ndash;145 bp was deleted. EMSA studies indicated that Pax6 and Pdx1 bind to this proximal sequence of the human GIP promoter. Our findings indicate that concomitant expression of Pax6 and Pdx1 is important for GIP expression. Our results also suggest that the presence of Pdx1 defines whether GLP-1-expressing gastrointestinal L cells also coexpress GIP.</P>
]]></description>
<dc:creator><![CDATA[Fujita, Y., Chui, J. W. Y., King, D. S., Zhang, T., Seufert, J., Pownall, S., Cheung, A. T., Kieffer, T. J.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90440.2008</dc:identifier>
<dc:title><![CDATA[Pax6 and Pdx1 are required for production of glucose-dependent insulinotropic polypeptide in proglucagon-expressing L cells]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E657</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E648</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E658?rss=1">
<title><![CDATA[Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E658?rss=1</link>
<description><![CDATA[ 
<P>Sepsis is a multifactorial, and often fatal, disorder typically characterized by widespread inflammation and immune activation with resultant endothelial activation. In the present study, we postulated that the adipokine adiponectin serves as a critical modulator of survival and endothelial activation in sepsis. To this aim, we evaluated both loss-of-function (adiponectin gene-deficient mice) and subsequent gain-of-function (recombinant adiponectin reconstitution) strategies in two well-established inflammatory models, cecal ligation perforation (CLP) and thioglyocollate-induced peritonitis. <I>Adipoq</I><SUP>&ndash;/&ndash;</SUP> mice, subjected to CLP, exhibited a profound (~8-fold) reduction in survival compared with their wild-type <I>Adipoq</I><SUP>+/+</SUP> littermates after 48 h. Furthermore, compared with wild-type controls, thioglycollate challenge resulted in a markedly greater influx of peritoneal neutrophils in <I>Adipoq</I><SUP>&ndash;/&ndash;</SUP> mice accompanied by an excess production of key chemoattractant cytokines (IL-12p70, TNF, MCP-1, and IL-6) and upregulation of aortic endothelial adhesion molecule VCAM-1 and ICAM-1 expressions. Importantly, all of these effects were blunted by recombinant total adiponectin administration given 3 days prior to thioglycollate challenge. The protective effects of adiponectin were ascribed largely to higher-order adiponectin oligomers, since administration of recombinant C39A trimeric adiponectin did not attenuate endothelial adhesion molecule expression in thioglycollate-challenged <I>Adipoq</I><SUP>&ndash;/&ndash;</SUP> mice. These data suggest a critical role of adiponectin as a modulator of survival and endothelial inflammation in experimental sepsis and a potential mechanistic link between adiposity and increased sepsis.</P>
]]></description>
<dc:creator><![CDATA[Teoh, H., Quan, A., Bang, K. W. A., Wang, G., Lovren, F., Vu, V., Haitsma, J. J., Szmitko, P. E., Al-Omran, M., Wang, C.-H., Gupta, M., Peterson, M. D., Zhang, H., Chan, L., Freedman, J., Sweeney, G., Verma, S.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90384.2008</dc:identifier>
<dc:title><![CDATA[Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E664</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E658</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E665?rss=1">
<title><![CDATA[Eliminating phosphorylation sites of the parathyroid hormone receptor type 1 differentially affects stimulation of phospholipase C and receptor internalization]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E665?rss=1</link>
<description><![CDATA[ 
<P>The parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor (PTH1R) belongs to family B of seven-transmembrane-spanning receptors and is activated by PTH and PTHrP. Upon PTH stimulation, the rat PTH1R becomes phosphorylated at seven serine residues. Elimination of all PTH1R phosphorylation sites results in prolonged cAMP accumulation and impaired internalization in stably transfected LLC-PK1 cells. The present study explores the role of individual PTH1R phosphorylation sites in PTH1R signaling through phospholipase C, agonist-dependent receptor internalization, and regulation by G protein-coupled receptor kinases. By means of transiently transfected COS-7 cells, we demonstrate that the phosphorylation-deficient (pd) PTH1R confers dramatically enhanced coupling to G<SUB>q/11</SUB> proteins upon PTH stimulation predominantly caused by elimination of Ser<SUP>491/492/493</SUP>, Ser<SUP>501</SUP>, or Ser<SUP>504</SUP>. Reportedly, impaired internalization of the pd PTH1R, however, is not dependent on a specific phosphorylation site. In addition, we show that G protein-coupled receptor kinase 2 interferes with pd PTH1R signaling to G<SUB>q/11</SUB> proteins at least partially by direct binding to G<SUB>q/11</SUB> proteins.</P>
]]></description>
<dc:creator><![CDATA[Miedlich, S. U., Abou-Samra, A. B.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00036.2008</dc:identifier>
<dc:title><![CDATA[Eliminating phosphorylation sites of the parathyroid hormone receptor type 1 differentially affects stimulation of phospholipase C and receptor internalization]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E671</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E665</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E672?rss=1">
<title><![CDATA[Metabolism and synthesis of arginine vasopressin in conscious newborn sheep]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E672?rss=1</link>
<description><![CDATA[ 
<P>Arginine vasopressin (AVP) is an important regulator of cardiovascular homeostasis in the fetus, but its role after birth is unclear. Although infused AVP increases mean arterial pressure (MAP) during the 1st mo after birth, pressor responses are unchanged, suggesting that vascular responsiveness is also unchanged. Alternatively, this could reflect increases in AVP metabolic clearance rate (MCR<SUB>AVP</SUB>). However, newborn AVP metabolism and synthesis are poorly studied. Therefore, we examined the pressor responses to infused AVP and the pattern of circulating AVP, AVP production rate (PR<SUB>AVP</SUB>), and MCR<SUB>AVP</SUB> in conscious newborn sheep (<I>n</I> = 5) at 9&ndash;38 days after birth. Basal MAP rose and heart rate (HR) fell during the study period (<I>P</I> &le; 0.02), while circulating AVP was unchanged (<I>P</I> &gt; 0.1), averaging 3.01 &plusmn; 0.86 pg/ml. Infused AVP elicited steady-state responses at 10&ndash;40 min, increasing plasma AVP and MAP and decreasing HR (<I>P</I> &lt; 0.001). Although pressor responses were unchanged between 9 and 38 days, the rise in MAP correlated with increases in plasma AVP (<I>R</I> = 0.47, <I>P</I> = 0.02, <I>n</I> = 24). MCR<SUB>AVP</SUB> was unchanged throughout the 1st mo (<I>P</I> &gt; 0.2), averaging 205 &plusmn; 17 ml&middot;kg<SUP>&ndash;1</SUP>&middot;min<SUP>&ndash;1</SUP>, and was associated with an elevated PR<SUB>AVP</SUB>, 973 &plusmn; 267 pg&middot;kg<SUP>&ndash;1</SUP>&middot;min<SUP>&ndash;1</SUP>, which also was unchanged (<I>P</I> &gt; 0.1). After birth, MCR<SUB>AVP</SUB> and PR<SUB>AVP</SUB> are elevated, probably accounting for the stable plasma AVP levels. The former is also likely to account for the stable pressor responses to infused AVP during the 1st mo. The reason for the elevated PR<SUB>AVP</SUB> is unclear but may relate to increases in vascular volume associated with postnatal growth.</P>
]]></description>
<dc:creator><![CDATA[Miao, D. C., Velaphi, S. C., Roy, T., DeSpain, K., Rosenfeld, C. R.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90441.2008</dc:identifier>
<dc:title><![CDATA[Metabolism and synthesis of arginine vasopressin in conscious newborn sheep]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E677</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E672</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E678?rss=1">
<title><![CDATA[Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E678?rss=1</link>
<description><![CDATA[ 
<P>Insulin resistance is a characteristic feature of type 2 diabetes and obesity. Insulin-resistant individuals manifest multiple disturbances in free fatty acid (FFA) metabolism and have excessive lipid accumulation in insulin target tissues. Although much evidence supports a causal role for altered FFA metabolism in the development of insulin resistance, i.e., "lipotoxicity", the intracellular mechanisms by which elevated plasma FFA levels cause insulin resistance have yet to be completely elucidated. Recent studies have implicated a possible role for mitochondrial dysfunction in the pathogenesis of insulin resistance in skeletal muscle. We examined the effect of FFA metabolites [palmitoyl carnitine (PC), palmitoyl-coenzyme A (CoA), and oleoyl-CoA] on ATP synthesis in mitochondria isolated from mouse and human skeletal muscle. At concentrations ranging from 0.5 to 2 &micro;M, these FFA metabolites stimulated ATP synthesis; however, above 5 &micro;M, there was a dose-response inhibition of ATP synthesis. Furthermore, 10 &micro;M PC inhibits ATP synthesis from pyruvate. Elevated PC concentrations (&ge;10 &micro;M) inhibit electron transport chain activity and decrease the mitochondrial inner membrane potential. These acquired mitochondrial defects, caused by a physiological increase in the concentration of FFA metabolites, provide a mechanistic link between lipotoxicity, mitochondrial dysfunction, and muscle insulin resistance.</P>
]]></description>
<dc:creator><![CDATA[Abdul-Ghani, M. A., Muller, F. L., Liu, Y., Chavez, A. O., Balas, B., Zuo, P., Chang, Z., Tripathy, D., Jani, R., Molina-Carrion, M., Monroy, A., Folli, F., Van Remmen, H., DeFronzo, R. A.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90287.2008</dc:identifier>
<dc:title><![CDATA[Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E685</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E678</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E686?rss=1">
<title><![CDATA[Oxytocin alleviates the neuroendocrine and cytokine response to bacterial endotoxin in healthy men]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E686?rss=1</link>
<description><![CDATA[ 
<P>Oxytocin is a hormone and neurotransmitter found to have anti-inflammatory functions in rodents. Here we used experimental bacterial endotoxinemia to examine the role of exogenous oxytocin administration on innate immune responses in humans. Ten healthy men received, in a randomized, placebo-controlled, crossover design, placebo, oxytocin, LPS, and LPS + oxytocin. Oxytocin treatment resulted in a transient or prolonged reduction of endotoxin-induced increases in plasma ACTH, cortisol, procalcitonin, TNF-, IL-1 receptor antagonist, IL-4, IL-6, macrophage inflammatory protein-1, macrophage inflammatory protein-1&beta;, monocyte chemoattractant protein-1 (MCP-1), interferon-inducible protein 10, and VEGF. In vitro, oxytocin had no impact on LPS effects in releasing TNF-, IL-6, and MCP-1 in monocytes and peripheral blood mononuclear cells from healthy human donors. In summary, oxytocin decreases the neuroendocrine and cytokine activation caused by bacterial endotoxin in men, possibly due to the pharmacological modulation of the cholinergic anti-inflammatory pathway. Oxytocin might be a candidate for the therapy of inflammatory diseases and conditions associated with high cytokine and VEGF levels.</P>
]]></description>
<dc:creator><![CDATA[Clodi, M., Vila, G., Geyeregger, R., Riedl, M., Stulnig, T. M., Struck, J., Luger, T. A., Luger, A.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90263.2008</dc:identifier>
<dc:title><![CDATA[Oxytocin alleviates the neuroendocrine and cytokine response to bacterial endotoxin in healthy men]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E691</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E686</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E692?rss=1">
<title><![CDATA[Effects of hyperinsulinemia on hepatic metalloproteinases and their tissue inhibitors]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E692?rss=1</link>
<description><![CDATA[ 
<P>To gain insight into the pathogenesis of hepatic fibrosis related to insulin resistance, we have examined the effects of euglycemic hyperinsulinemia on three matrix metalloproteinases (MMP-2, MMP-9, and MT1-MMP) and on two major tissue inhibitors of MMPs (TIMP-1 and TIMP-2) in liver of insulin-sensitive and insulin-resistant rats. Four hours of insulin infusion (4.8 mU&middot;kg<SUP>&ndash;1</SUP>&middot;min<SUP>&ndash;1</SUP>) without or with lipid-heparin infusion (to produce insulin resistance) decreased hepatic MMP-2 mRNA (by RT-PCR), pro-MMP-2, MMP-2, MMP-9, and MT1-MMP (all by Western blots) and the gelatinolytic activity of MMP-2 (by gelatin zymography) by ~60&ndash;80%. Hyperinsulinemia (~1.6 mmol/l) increased TIMP-1 and TIMP-2 concentrations (by ELISA) in insulin-sensitive and insulin-resistant rats. Phosphoinositide 3-kinase was activated by insulin in insulin-sensitive rats and inhibited in insulin-resistant rats. Extracellular signal-regulated kinases 1/2 (ERK1/2) were activated by insulin in insulin-sensitive rats and partially inhibited in insulin-resistant rats; c-jun NH<SUB>2</SUB>-terminal kinase-1 (JNK1), JNK2/3, or p38 MAPK were only activated by lipid but not by insulin. We conclude that hyperinsulinemia, whether or not associated with insulin resistance, shifts the MMP/TIMP balance toward reduction of extracellular matrix degradation and thus may promote the development of hepatic fibrosis.</P>
]]></description>
<dc:creator><![CDATA[Boden, G., Song, W., Kresge, K., Mozzoli, M., Cheung, P.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90370.2008</dc:identifier>
<dc:title><![CDATA[Effects of hyperinsulinemia on hepatic metalloproteinases and their tissue inhibitors]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E697</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E692</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E698?rss=1">
<title><![CDATA[CaMK activation during exercise is required for histone hyperacetylation and MEF2A binding at the MEF2 site on the Glut4 gene]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E698?rss=1</link>
<description><![CDATA[ 
<P>The role of CaMK II in regulating GLUT4 expression in response to intermittent exercise was investigated. Wistar rats completed 5 <FONT FACE="arial,helvetica">x</FONT> 17-min bouts of swimming after receiving 5 mg/kg KN93 (a CaMK II inhibitor), KN92 (an analog of KN93 that does not inhibit CaMK II), or an equivalent volume of vehicle. Triceps muscles that were harvested at 0, 6, or 18 h postexercise were assayed for <I>1</I>) CaMK II phosphorylation by Western blot, <I>2</I>) acetylation of histone H3 at the <I>Glut4</I> MEF2 site by chromatin immunoprecipitation (ChIP) assay, <I>3</I>) bound MEF2A at the <I>Glut4</I> MEF2 <I>cis</I>-element by ChIP, and <I>4</I>) GLUT4 expression by RT-PCR and Western blot. Compared with controls, exercise caused a twofold increase in CaMK II phosphorylation. Immunohistochemical stains indicated increased CaMK II phosphorylation in nuclear and perinuclear regions of the muscle fiber. Acetylation of histone H3 in the region surrounding the MEF2 binding site on the <I>Glut4</I> gene and the amount of MEF2A that bind to the site increased approximately twofold postexercise. GLUT4 mRNA and protein increased ~2.2- and 1.8-fold, respectively, after exercise. The exercise-induced increases in CaMK II phosphorylation, histone H3 acetylation, MEF2A binding, and GLUT4 expression were attenuated or abolished when KN93 was administered to rats prior to exercise. KN92 did not affect the increases in pCaMK II and GLUT4. These data support the hypothesis that CaMK II activation by exercise increases GLUT4 expression via increased accessibility of MEF2A to its <I>cis</I>-element on the gene.</P>
]]></description>
<dc:creator><![CDATA[Smith, J. A. H., Kohn, T. A., Chetty, A. K., Ojuka, E. O.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00747.2007</dc:identifier>
<dc:title><![CDATA[CaMK activation during exercise is required for histone hyperacetylation and MEF2A binding at the MEF2 site on the Glut4 gene]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E704</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E698</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E705?rss=1">
<title><![CDATA[Cardiac metabolic compensation to hypertension requires lipoprotein lipase]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E705?rss=1</link>
<description><![CDATA[ 
<P>Fatty acids (FAs) are acquired from free FA associated with albumin and lipoprotein triglyceride that is hydrolyzed by lipoprotein lipase (LpL). Hypertrophied hearts shift their substrate usage pattern to more glucose and less FA. However, FAs may still be an important source of energy in hypertrophied hearts. The aim of this study was to examine the importance of LpL-derived FAs in hypertensive hypertrophied hearts. We followed cardiac function and metabolic changes during 2 wk of angiotensin II (ANG II)-induced hypertension in control and heart-specific lipoprotein lipase knockout (hLpL0) mice. Glucose metabolism was increased in ANG II-treated control (control/ANG II) hearts, raising it to the same level as hLpL0 hearts. FA uptake-related genes, CD36 and FATP1, were reduced in control/ANG II hearts to levels found in hLpL0 hearts. ANG II did not alter these metabolic genes in hLpL0 mice. LpL activity was preserved, and mitochondrial FA oxidation-related genes were not altered in control/ANG II hearts. In control/ANG II hearts, triglyceride stores were consumed and reached the same levels as in hLpL0/ANG II hearts. Intracellular ATP content was reduced only in hLpL0/ANG II hearts. Both ANG II and deoxycorticosterone acetate-salt induced hypertension caused heart failure only in hLpL0 mice. Our data suggest that LpL activity is required for normal cardiac metabolic compensation to hypertensive stress.</P>
]]></description>
<dc:creator><![CDATA[Yamashita, H., Bharadwaj, K. G., Ikeda, S., Park, T.-S., Goldberg, I. J.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90338.2008</dc:identifier>
<dc:title><![CDATA[Cardiac metabolic compensation to hypertension requires lipoprotein lipase]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E713</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E705</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E714?rss=1">
<title><![CDATA[Short-term flexibility of myocardial triglycerides and diastolic function in patients with type 2 diabetes mellitus]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E714?rss=1</link>
<description><![CDATA[ 
<P>Short-term caloric restriction increases plasma levels of nonesterified fatty acids (NEFAs) and is associated with increased myocardial triglyceride (TG) content and decreased myocardial function in healthy subjects. Whether this flexibility of myocardial TG stores and myocardial function is also present in patients with type 2 diabetes mellitus (T2DM) is yet unknown. Myocardial TG content and left ventricular (LV) ratio between the early (E) and atrial (A) diastolic filling phase (E/A) were determined using magnetic resonance (MR) spectroscopy and MR imaging, respectively, before and after a 3-day very low-calorie diet (VLCD) in 11 patients with T2DM. In addition, we studied patients after a 3-day VLCD combined with the antilipolytic drug acipimox. The VLCD induced myocardial TG accumulation [from 0.66 &plusmn; 0.09% (mean &plusmn; SE, baseline) to 0.98 &plusmn; 0.16%, <I>P</I> = 0.028] and a decrease in E/A ratio [from 1.00 &plusmn; 0.05 (baseline) to 0.90 &plusmn; 0.06, <I>P</I> = 0.002]. This was associated with increased plasma NEFA levels (from 0.57 &plusmn; 0.08 mmol/l at baseline to 0.92 &plusmn; 0.12, <I>P =</I> 0.019). After the VLCD with acipimox, myocardial TG content, diastolic function, and plasma NEFA levels were similar to baseline values. In conclusion, in patients with T2DM, a VLCD increases myocardial TG content and is associated with a decrease in LV diastolic function. These effects were not observed when a VLCD was combined with acipimox, illustrating the physiological flexibility of myocardial TG stores and myocardial function in patients with T2DM.</P>
]]></description>
<dc:creator><![CDATA[Hammer, S., van der Meer, R. W., Lamb, H. J., de Boer, H. H., Bax, J. J., de Roos, A., Romijn, J. A., Smit, J. W. A.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90413.2008</dc:identifier>
<dc:title><![CDATA[Short-term flexibility of myocardial triglycerides and diastolic function in patients with type 2 diabetes mellitus]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E718</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E714</prism:startingPage>
<prism:section>INNOVATIVE METHODOLOGY</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/3/E719?rss=1">
<title><![CDATA[Effects of adlay hull extracts on uterine contraction and Ca2+ mobilization in the rat]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/3/E719?rss=1</link>
<description><![CDATA[ 
<P>Dysmenorrhea is directly related to elevated PGF<SUB>2</SUB> levels. It is treated with nonsteroid antiinflammatory drugs (NSAIDs) in Western medicine. Since NSAIDs produce many side effects, Chinese medicinal therapy is considered as a feasible alternative medicine. Adlay (<I>Coix lachryma-jobi</I> L. var. <I>ma-yuen</I> Stapf.) has been used as a traditional Chinese medicine for treating dysmenorrhea. However, the relationship between smooth muscle contraction and adlay extracts remains veiled. Therefore, we investigated this relationship in the rat uterus by measuring uterine contraction activity and recording the intrauterine pressure. We studied the in vivo and in vitro effects of the methanolic extracts of adlay hull (AHM) on uterine smooth muscle contraction. The extracts were fractionated using four different solvents: water, 1-butanol, ethyl acetate, and <I>n</I>-hexane; the four respective fractions were AHM-Wa, AHM-Bu, AHM-EA, and AHM-Hex. AHM-EA and its subfractions (175 &micro;g/ml) inhibited uterine contractions induced by PGF<SUB>2</SUB>, the Ca<SUP>2+</SUP> channel activator Bay K 8644, and high K<SUP>+</SUP> in a concentration-dependent manner in vitro. AHM-EA also inhibited PGF<SUB>2</SUB>-induced uterine contractions in vivo; furthermore, 375 &micro;g/ml of AHM-EA inhibited the Ca<SUP>2+</SUP>-dependent uterine contractions. Thus 375 &micro;g/ml of AHM-EA consistently suppressed the increases in intracellular Ca<SUP>2+</SUP> concentrations induced by PGF<SUB>2</SUB> and high K<SUP>+</SUP>. We also demonstrated that naringenin and quercetin are the major pure chemical components of AHM-EA that inhibit PGF<SUB>2</SUB>-induced uterine contractions. Thus AHM-EA probably inhibited uterine contraction by blocking external Ca<SUP>2+</SUP> influx, leading to a decrease in intracellular Ca<SUP>2+</SUP> concentration. Thus adlay hull may be considered as a feasible alternative therapeutic agent for dysmenorrhea.</P>
]]></description>
<dc:creator><![CDATA[Hsia, S.-M., Kuo, Y.-H., Chiang, W., Wang, P. S.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90367.2008</dc:identifier>
<dc:title><![CDATA[Effects of adlay hull extracts on uterine contraction and Ca2+ mobilization in the rat]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E726</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E719</prism:startingPage>
<prism:section>TRANSLATIONAL PHYSIOLOGY</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/full/295/3/E727?rss=1">
<title><![CDATA[Regulatory role of translocation of Na+-K+ pumps in skeletal muscle: hypothesis or reality?]]></title>
<link>http://ajpendo.physiology.org/cgi/content/full/295/3/E727?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Clausen, T.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90494.2008</dc:identifier>
<dc:title><![CDATA[Regulatory role of translocation of Na+-K+ pumps in skeletal muscle: hypothesis or reality?]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E728</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E727</prism:startingPage>
<prism:section>LETTERS TO THE EDITOR</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/full/295/3/E729?rss=1">
<title><![CDATA[Reply to Clausen letter]]></title>
<link>http://ajpendo.physiology.org/cgi/content/full/295/3/E729?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Chibalin, A. V., Benziane, B.]]></dc:creator>
<dc:date>2008-09-04</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90537.2008</dc:identifier>
<dc:title><![CDATA[Reply to Clausen letter]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>3</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E729</prism:endingPage>
<prism:publicationDate>2008-09-01</prism:publicationDate>
<prism:startingPage>E729</prism:startingPage>
<prism:section>LETTERS TO THE EDITOR</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/full/295/2/E225?rss=1">
<title><![CDATA[Insight into the "odd" hexose transporters GLUT3, GLUT5, and GLUT7]]></title>
<link>http://ajpendo.physiology.org/cgi/content/full/295/2/E225?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Schurmann, A.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90406.2008</dc:identifier>
<dc:title><![CDATA[Insight into the "odd" hexose transporters GLUT3, GLUT5, and GLUT7]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E226</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E225</prism:startingPage>
<prism:section>EDITORIAL FOCUS</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E227?rss=1">
<title><![CDATA[Regulation of the fructose transporter GLUT5 in health and disease]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E227?rss=1</link>
<description><![CDATA[ 
<P>Fructose is now such an important component of human diets that increasing attention is being focused on the fructose transporter GLUT5. In this review, we describe the regulation of GLUT5 not only in the intestine and testis, where it was first discovered, but also in the kidney, skeletal muscle, fat tissue, and brain where increasing numbers of cell types have been found to have GLUT5. GLUT5 expression levels and fructose uptake rates are also significantly affected by diabetes, hypertension, obesity, and inflammation and seem to be induced during carcinogenesis, particularly in the mammary glands. We end by highlighting research areas that should yield information needed to better understand the role of GLUT5 during normal development, metabolic disturbances, and cancer.</P>
]]></description>
<dc:creator><![CDATA[Douard, V., Ferraris, R. P.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90245.2008</dc:identifier>
<dc:title><![CDATA[Regulation of the fructose transporter GLUT5 in health and disease]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E237</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E227</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E238?rss=1">
<title><![CDATA[GLUT7: a new intestinal facilitated hexose transporter]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E238?rss=1</link>
<description><![CDATA[ 
<P>The very last member of the SLC2A gene family of facilitated hexose transporters to be cloned was SLC2A7 (hGLUT7). It has been assigned to the class II of the GLUT family on the basis of sequence similarity, and its closest family member is GLUT5, an intestinal fructose transporter. GLUT7 is primarily expressed in the small intestine and colon, although mRNA has been detected in the testis and prostate as well. The protein is expressed in the apical membrane of the small intestine and colon, and it has a high affinity (&lt;0.5 mM) for glucose and fructose. The abundance of the protein in the small intestine does change in parallel with the dietary carbohydrate. However, the distribution of GLUT7 along the small intestine does not entirely match with the availability of glucose and fructose, suggesting that the physiological substrate for this transporter has yet to be identified. Unlike GLUT13, the proton-coupled myoinositol transporter (HMIT), there is no evidence for the coupling of protons to the hexose movement via GLUT7. One area of study in which GLUT7 has provided a useful comparison with GLUT1 has been in the development of the hypothesis that the facilitated hexose transporters may have a selectivity filter at the exofacial opening of the translocation pore, which helps to determine which hexoses can be transported. If substantiated, the elucidation of this mechanism may prove useful in the design of hexose analogs for use in cancer imaging and therapeutics.</P>
]]></description>
<dc:creator><![CDATA[Cheeseman, C.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90394.2008</dc:identifier>
<dc:title><![CDATA[GLUT7: a new intestinal facilitated hexose transporter]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E241</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E238</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E242?rss=1">
<title><![CDATA[The facilitative glucose transporter GLUT3: 20 years of distinction]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E242?rss=1</link>
<description><![CDATA[ 
<P>Glucose metabolism is vital to most mammalian cells, and the passage of glucose across cell membranes is facilitated by a family of integral membrane transporter proteins, the GLUTs. There are currently 14 members of the SLC2 family of GLUTs, several of which have been the focus of this series of reviews. The subject of the present review is GLUT3, which, as implied by its name, was the third glucose transporter to be cloned (Kayano T, Fukumoto H, Eddy RL, Fan YS, Byers MG, Shows TB, Bell GI. <I>J Biol Chem</I> 263: 15245&ndash;15248, 1988) and was originally designated as the neuronal GLUT. The overriding question that drove the early work on GLUT3 was why would neurons need a separate glucose transporter isoform? What is it about GLUT3 that specifically suits the needs of the highly metabolic and oxidative neuron with its high glucose demand? More recently, GLUT3 has been studied in other cell types with quite specific requirements for glucose, including sperm, preimplantation embryos, circulating white blood cells, and an array of carcinoma cell lines. The last are sufficiently varied and numerous to warrant a review of their own and will not be discussed here. However, for each of these cases, the same questions apply. Thus, the objective of this review is to discuss the properties and tissue and cellular localization of GLUT3 as well as the features of expression, function, and regulation that distinguish it from the rest of its family and make it uniquely suited as the mediator of glucose delivery to these specific cells.</P>
]]></description>
<dc:creator><![CDATA[Simpson, I. A., Dwyer, D., Malide, D., Moley, K. H., Travis, A., Vannucci, S. J.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90388.2008</dc:identifier>
<dc:title><![CDATA[The facilitative glucose transporter GLUT3: 20 years of distinction]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E253</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E242</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E254?rss=1">
<title><![CDATA[Pathogenic role of Fgf23 in Dmp1-null mice]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E254?rss=1</link>
<description><![CDATA[ 
<P>Autosomal recessive hypophosphatemic rickets (ARHR), which is characterized by renal phosphate wasting, aberrant regulation of 1-hydroxylase activity, and rickets/osteomalacia, is caused by inactivating mutations of dentin matrix protein 1 (<I>DMP1</I>). ARHR resembles autosomal dominant hypophosphatemic rickets (ADHR) and X-linked hypophosphatemia (XLH), hereditary disorders respectively caused by cleavage-resistant mutations of the phosphaturic factor FGF23 and inactivating mutations of PHEX that lead to increased production of FGF23 by osteocytes in bone. Circulating levels of FGF23 are increased in ARHR and its <I>Dmp1</I>-null mouse homologue. To determine the causal role of FGF23 in ARHR, we transferred <I>Fgf23</I> deficient/enhanced green fluorescent protein (eGFP) reporter mice onto <I>Dmp1</I>-null mice to create mice lacking both <I>Fgf23</I> and <I>Dmp1</I>. <I>Dmp1</I><SUP>&ndash;/&ndash;</SUP> mice displayed decreased serum phosphate concentrations, inappropriately normal 1,25(OH)<SUB>2</SUB>D levels, severe rickets, and a diffuse form of osteomalacia in association with elevated Fgf23 serum levels and expression in osteocytes. In contrast, <I>Fgf23</I><SUP>&ndash;/&ndash;</SUP> mice had undetectable serum Fgf23 and elevated serum phosphate and 1,25(OH)<SUB>2</SUB>D levels along with severe growth retardation and focal form of osteomalacia. In combined <I>Dmp1</I><SUP>&ndash;/&ndash;</SUP>/Fgf23<SUP>&ndash;/&ndash;</SUP>, circulating Fgf23 levels were also undetectable, and the serum levels of phosphate and 1,25(OH)<SUB>2</SUB>D levels were identical to Fgf23<SUP>&ndash;/&ndash;</SUP> mice. Rickets and diffuse osteomalacia in <I>Dmp1</I>-null mice were transformed to severe growth retardation and focal osteomalacia characteristic of <I>Fgf23</I>-null mice. These data suggest that the regulation of extracellular matrix mineralization by DMP1 is coupled to renal phosphate handling and vitamin D metabolism through a DMP1-dependent regulation of FGF23 production by osteocytes.</P>
]]></description>
<dc:creator><![CDATA[Liu, S., Zhou, J., Tang, W., Menard, R., Feng, J. Q., Quarles, L. D.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90201.2008</dc:identifier>
<dc:title><![CDATA[Pathogenic role of Fgf23 in Dmp1-null mice]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E261</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E254</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E262?rss=1">
<title><![CDATA[Transient prenatal androgen exposure produces metabolic syndrome in adult female rats]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E262?rss=1</link>
<description><![CDATA[ 
<P>Androgen exposure during intrauterine life in nonhuman primates and in sheep results in a phenocopy of the reproductive and metabolic features of polycystic ovary syndrome (PCOS). Such exposure also results in reproductive features of PCOS in rodents. We investigated whether transient prenatal androgen treatment produced metabolic abnormalities in adult female rats and the mechanisms of these changes. Pregnant dams received free testosterone or vehicle injections during late gestation, and their female offspring were fed regular or high-fat diet (HFD). At 60 days of age, prenatally androgenized (PA) rats exhibited significantly increased body weight; parametrial and subcutaneous fat; serum insulin, cholesterol and triglyceride levels; and hepatic triglyceride content (all <I>P</I> &lt; 0.0125). There were no significant differences in insulin sensitivity by intraperitoneal insulin tolerance test or insulin signaling in liver or skeletal muscle. HFD had similar effects to PA on body weight and composition as well as on circulating triglyceride levels. HFD further increased hepatic triglyceride content to a similar extent in both PA and control rats. In PA rats, HFD did not further increase circulating insulin, triglyceride, or cholesterol levels. In control rats, HFD increased insulin levels, but to a lesser extent than PA alone (~2.5- vs. ~12-fold, respectively). We conclude that transient prenatal androgen exposure produces features of the metabolic syndrome in adult female rats. Dyslipidemia and hepatic steatosis appear to be mediated by PA-induced increases in adiposity, whereas hyperinsulinemia appears to be a direct result of PA.</P>
]]></description>
<dc:creator><![CDATA[Demissie, M., Lazic, M., Foecking, E. M., Aird, F., Dunaif, A., Levine, J. E.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90208.2008</dc:identifier>
<dc:title><![CDATA[Transient prenatal androgen exposure produces metabolic syndrome in adult female rats]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E268</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E262</prism:startingPage>
<prism:section>TRANSLATIONAL PHYSIOLOGY</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E269?rss=1">
<title><![CDATA[Exenatide can reduce glucose independent of islet hormones or gastric emptying]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E269?rss=1</link>
<description><![CDATA[ 
<P>Exenatide is a long-acting glucagon-like peptide-1 (GLP-1) mimetic used in the treatment of type 2 diabetes. There is increasing evidence that GLP-1 can influence glycemia not only via pancreatic (insulinotropic and glucagon suppression) and gastric-emptying effects, but also via an independent mechanism mediated by portal vein receptors. The aim of our study was to investigate whether exenatide has an islet- and gastric-independent glycemia-reducing effect, similar to GLP-1. First, we administered mixed meals, with or without exenatide (20 &micro;g sc) to dogs. Second, to determine whether exenatide-induced reduction in glycemia is independent of slower gastric emptying, in the same animals we infused glucose intraportally (to simulate meal test glucose appearance) with exenatide, exenatide + the intraportal GLP-1 receptor antagonist exendin-(9-39), or saline. Exenatide markedly decreased postprandial glucose: net 0- to 135-min area under the curve = +526 &plusmn; 315 and &ndash;536 &plusmn; 197 mg&middot;dl<SUP>&ndash;1</SUP>&middot;min<SUP>&ndash;1</SUP> with saline and exenatide, respectively (<I>P</I> &lt; 0.05). Importantly, the decrease in plasma glucose occurred without a corresponding increase in postprandial insulin but was accompanied by delayed gastric emptying and lower glucagon. Significantly lower glycemia was induced by intraportal glucose infusion with exenatide than with saline (92 &plusmn; 1 vs. 97 &plusmn; 1 mg/dl, <I>P</I> &lt; 0.001) in the absence of hyperinsulinemia or glucagon suppression. The exenatide-induced lower glycemia was partly reversed by intraportal exendin-(9-39): 95 &plusmn; 3 and 92 &plusmn; 3 mg/dl with exenatide + antagonist and exenatide, respectively (<I>P</I> &lt; 0.01). Our results suggest that, similar to GLP-1, exenatide lowers glycemia via a novel mechanism independent of islet hormones and slowing of gastric emptying. We hypothesize that receptors in the portal vein, via a neural mechanism, increase glucose clearance independent of islet hormones.</P>
]]></description>
<dc:creator><![CDATA[Ionut, V., Zheng, D., Stefanovski, D., Bergman, R. N.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90222.2008</dc:identifier>
<dc:title><![CDATA[Exenatide can reduce glucose independent of islet hormones or gastric emptying]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E277</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E269</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E278?rss=1">
<title><![CDATA[Relaxin-3 stimulates the hypothalamic-pituitary-gonadal axis]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E278?rss=1</link>
<description><![CDATA[ 
<P>The hypothalamus plays a key role in the regulation of both energy homeostasis and reproduction. Evidence suggests that relaxin-3, a recently discovered member of the insulin superfamily, is an orexigenic hypothalamic neuropeptide. Relaxin-3 is thought to act in the brain via the RXFP3 receptor, although the RXFP1 receptor may also play a role. Relaxin-3, RXFP3, and RXFP1 are present in the hypothalamic paraventricular nucleus, an area with a well-characterized role in the regulation of energy balance that also modulates reproductive function by providing inputs to hypothalamic gonadotropin-releasing hormone (GnRH) neurons. Other members of the relaxin family are known to play a role in the regulation of reproduction. However, the effects of relaxin-3 on reproductive function are unknown. We studied the role of relaxin-3 in the regulation of the hypothalamo-pituitary-gonadal (HPG) axis. Intracerebroventricular (5 nmol) and intraparaventricular (540&ndash;1,620 pmol) administration of human relaxin-3 (H3) in adult male Wistar rats significantly increased plasma luteinizing hormone (LH) 30 min postinjection. This effect was blocked by pretreatment with a peripheral GnRH antagonist. Central administration of human relaxin-2 showed no significant effect on plasma LH. H3 dose-dependently stimulated the release of GnRH from hypothalamic explants and GT<SUB>1</SUB>-7 cells, which express RXFP1 and RXFP3, but did not influence LH or follicle-stimulating hormone release from pituitary fragments in vitro. We have demonstrated a novel role for relaxin-3 in the stimulation of the HPG axis, putatively via hypothalamic GnRH neurons. Relaxin-3 may act as a central signal linking nutritional status and reproductive function.</P>
]]></description>
<dc:creator><![CDATA[McGowan, B. M., Stanley, S. A., Donovan, J., Thompson, E. L., Patterson, M., Semjonous, N. M., Gardiner, J. V., Murphy, K. G., Ghatei, M. A., Bloom, S. R.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00028.2008</dc:identifier>
<dc:title><![CDATA[Relaxin-3 stimulates the hypothalamic-pituitary-gonadal axis]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E286</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E278</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E287?rss=1">
<title><![CDATA[Thermogenically competent nonadrenergic recruitment in brown preadipocytes by a PPAR{gamma} agonist]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E287?rss=1</link>
<description><![CDATA[ 
<P>Most physiologically induced examples of recruitment of brown adipose tissue (BAT) occur as a consequence of chronic sympathetic stimulation (norepinephrine release within the tissue). However, in some physiological contexts (e.g., prenatal and prehibernation recruitment), this pathway is functionally contraindicated. Thus a nonsympathetically mediated mechanism of BAT recruitment must exist. Here we have tested whether a PPAR activation pathway could competently recruit BAT, independently of sympathetic stimulation. We continuously treated primary cultures of mouse brown (pre)adipocytes with the potent peroxisome proliferator-activated receptor- (PPAR) agonist rosiglitazone. In rosiglitazone-treated cultures, morphological signs of adipose differentiation and expression levels of the general adipogenic marker aP2 were manifested much earlier than in control cultures. Importantly, in the presence of the PPAR agonist the brown adipocyte phenotype was significantly enhanced: UCP1 was expressed even in the absence of norepinephrine, and PPAR expression and norepinephrine-induced PGC-1 mRNA levels were significantly increased. However, the augmented levels of PPAR could not explain the brown-fat promoting effect of rosiglitazone, as this effect was still evident in PPAR-null cells. In continuously rosiglitazone-treated brown adipocytes, mitochondriogenesis, an essential part of BAT recruitment, was significantly enhanced. Most importantly, these mitochondria were capable of thermogenesis, as rosiglitazone-treated brown adipocytes responded to the addition of norepinephrine with a large increase in oxygen consumption. This thermogenic response was not observable in rosiglitazone-treated brown adipocytes originating from UCP1-ablated mice; hence, it was UCP1 dependent. Thus the PPAR pathway represents an alternative, potent, and fully competent mechanism for BAT recruitment, which may be the cellular explanation for the enigmatic recruitment in prehibernation and prenatal states.</P>
]]></description>
<dc:creator><![CDATA[Petrovic, N., Shabalina, I. G., Timmons, J. A., Cannon, B., Nedergaard, J.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00035.2008</dc:identifier>
<dc:title><![CDATA[Thermogenically competent nonadrenergic recruitment in brown preadipocytes by a PPAR{gamma} agonist]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E296</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E287</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E297?rss=1">
<title><![CDATA[Pharmacological activation of PPAR{beta} promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E297?rss=1</link>
<description><![CDATA[ 
<P>Recent studies have shown that administration of peroxisome proliferator-activated receptor-&beta; (PPAR&beta;) agonists enhances fatty acid oxidation in rodent and human skeletal muscle and that muscle-restricted PPAR&beta; overexpression affects muscle metabolic profile by increasing oxidative myofiber number, which raises the possibility that PPAR&beta; agonists alter muscle morphology in adult animals. This possibility was examined in this study in which adult mice were treated with a PPAR&beta; agonist, and the resulting changes in myofiber metabolic phenotype and angiogenesis were quantified in tibialis anterior muscles. The findings indicate a muscle remodeling that is completed within 2 days and is characterized by a 1.63-fold increase in oxidative fiber number and by a 1.55-fold increase in capillary number. These changes were associated with a quick and transient upregulation of myogenic and angiogenic markers. Both myogenic and angiogenic responses were dependent on the calcineurin pathway, as they were blunted by cyclosporine A administration. In conclusion, the data indicate that PPAR&beta; activation is associated with a calcineurin-dependent effect on muscle morphology that enhances the oxidative phenotype.</P>
]]></description>
<dc:creator><![CDATA[Gaudel, C., Schwartz, C., Giordano, C., Abumrad, N. A., Grimaldi, P. A.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00581.2007</dc:identifier>
<dc:title><![CDATA[Pharmacological activation of PPAR{beta} promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E304</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E297</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E305?rss=1">
<title><![CDATA[Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E305?rss=1</link>
<description><![CDATA[ 
<P>An increase in angiotensin II (ANG II) under conditions of high salt intake can result in renal damage. The extent to which ANG II does this directly or by way of stimulating aldosterone (Aldo) secretion is a subject of some debate. In the present study, we sought to determine the separate effects of Aldo and ANG II on the expression of plasminogen activator inhibitor-1 (PAI-1) and other factors related to renal fibrosis in the stroke-prone spontaneously hypertensive rat (SHRSP). Saline-drinking male SHRSPs underwent adrenalectomy (ADX) or sham operation (Sham). Treatment groups consisted of ADX + ANG II (25 ng/min sc) and ADX + Aldo (40 &micro;g&middot;kg<SUP>&ndash;1</SUP>&middot;day<SUP>&ndash;1</SUP> sc). After 2 wk of treatment, circulating Aldo levels were reduced to the limit of detection, renal PAI-1, transforming growth factor-&beta;1 (TGF-&beta;1), and osteopontin expression, and phospho-Smad2 (p-Smad2) level were decreased severalfold, and Smad7 (an inhibitory regulator of TGF-&beta;1 action) expression was increased in ADX compared with Sham rats. Infusion of Aldo into ADX SHRSPs restored the renal mRNA expression of PAI-1, TGF-&beta;1 (along with restored p-Smad2 level), and osteopontin and reduced that of Smad7, whereas ANG II had no or a lesser effect. The findings were confirmed by histological examination of renal tissue. In summary, in the saline-drinking SHRSP, Aldo increased renal profibrotic factors and produced renal injury whereas ANG II in the absence of the adrenals had no effect.</P>
]]></description>
<dc:creator><![CDATA[Chun, T.-Y., Chander, P. N., Kim, J.-W., Pratt, J. H., Stier, C. T.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00512.2007</dc:identifier>
<dc:title><![CDATA[Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E312</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E305</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E313?rss=1">
<title><![CDATA[Macrophage infiltration into adipose tissue may promote angiogenesis for adipose tissue remodeling in obesity]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E313?rss=1</link>
<description><![CDATA[ 
<P>The biological role of macrophage infiltration into adipose tissue in obesity remains to be fully understood. We hypothesize that macrophages may act to stimulate angiogenesis in the adipose tissue. This possibility was examined by determining macrophage expression of angiogenic factor PDGF (platelet-derived growth factor) and regulation of tube formation of endothelial cells by PDGF. The data suggest that endothelial cell density was reduced in the adipose tissue of <I>ob/ob</I> mice. Expression of endothelial marker CD31 was decreased in protein and mRNA. The reduction was associated with an increase in macrophage infiltration. In the obese mice, PDGF concentration was elevated in the plasma, and its mRNA expression was increased in adipose tissue. Macrophages were found to be a major source of PDGF in adipose tissue, as deletion of macrophages led to a significant reduction in PDGF mRNA. In cell culture, PDGF expression was induced by hypoxia, and tube formation of endothelial cells was induced by PDGF. The PDGF activity was dependent on S6K, as inhibition of S6K in endothelial cells led to inhibition of the PDGF activity. We conclude that, in response to the reduced vascular density, macrophages may express PDGF in adipose tissue to facilitate capillary formation in obesity. Although the PDGF level is elevated in adipose tissue, its activity in angiogenesis is dependent on the availability of sufficient endothelial cells. The study suggests a new function of macrophages in the adipose tissue in obesity.</P>
]]></description>
<dc:creator><![CDATA[Pang, C., Gao, Z., Yin, J., Zhang, J., Jia, W., Ye, J.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90296.2008</dc:identifier>
<dc:title><![CDATA[Macrophage infiltration into adipose tissue may promote angiogenesis for adipose tissue remodeling in obesity]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E322</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E313</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E323?rss=1">
<title><![CDATA[Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E323?rss=1</link>
<description><![CDATA[ 
<P>A diet high in fat induces cardiac hypertrophy, inflammation, and oxidative stress. Although such actions have largely been ascribed to fat deposition, the accumulation of advanced glycation end products (AGEs) and subsequent activation of the receptor for AGEs (RAGE) may also represent important mediators of cardiac injury following exposure to a Western diet. In this study, male C57BL6J and <I>RAGE</I> knockout mice were placed on either a standard diet (7% fat) or a Western "fast-food" diet (21% fat). Animals receiving a high-fat diet were further randomized to receive the AGE inhibitor alagebrium chloride (1 mg&middot;kg<SUP>&ndash;1</SUP>&middot;day<SUP>&ndash;1</SUP>) and followed for 16 wk. A Western diet was associated with cardiac hypertrophy, inflammation, mitochondrial-dependent superoxide production, and cardiac AGE accumulation in wild-type mice. Although <I>RAGE</I>-KO mice fed a Western diet also became obese and accumulated intramyocardial lipid, cardiomyocyte hypertrophy, inflammation, and oxidative stress were attenuated compared with wild-type mice. Similarly, mice of both strains receiving alagebrium chloride had reduced levels of inflammation and oxidative stress, in association with a reduction in cardiac AGEs and RAGE. This study suggests that AGEs represent important mediators of cardiac injury associated with a Western fast-food diet. These data point to the potential utility of AGE-reducing strategies in the prevention and management of cardiac disease.</P>
]]></description>
<dc:creator><![CDATA[Tikellis, C., Thomas, M. C., Harcourt, B. E., Coughlan, M. T., Pete, J., Bialkowski, K., Tan, A., Bierhaus, A., Cooper, M. E., Forbes, J. M.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00024.2008</dc:identifier>
<dc:title><![CDATA[Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E330</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E323</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E331?rss=1">
<title><![CDATA[Loss of resistin ameliorates hyperlipidemia and hepatic steatosis in leptin-deficient mice]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E331?rss=1</link>
<description><![CDATA[ 
<P>Resistin has been linked to components of the metabolic syndrome, including obesity, insulin resistance, and hyperlipidemia. We hypothesized that resistin deficiency would reverse hyperlipidemia in genetic obesity. C57Bl/6J mice lacking resistin [resistin knockout (RKO)] had similar body weight and fat as wild-type mice when fed standard rodent chow or a high-fat diet. Nonetheless, hepatic steatosis, serum cholesterol, and very low-density lipoprotein (VLDL) secretion were decreased in diet-induced obese RKO mice. Resistin deficiency exacerbated obesity in <I>ob/ob</I> mice, but hepatic steatosis was drastically attenuated. Moreover, the levels of triglycerides, cholesterol, insulin, and glucose were reduced in <I>ob/ob</I>-RKO mice. The antisteatotic effect of resistin deficiency was related to reductions in the expression of genes involved in hepatic lipogenesis and VLDL export. Together, these results demonstrate a crucial role of resistin in promoting hepatic steatosis and hyperlipidemia in obese mice.</P>
]]></description>
<dc:creator><![CDATA[Singhal, N. S., Patel, R. T., Qi, Y., Lee, Y.-S., Ahima, R. S.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00577.2007</dc:identifier>
<dc:title><![CDATA[Loss of resistin ameliorates hyperlipidemia and hepatic steatosis in leptin-deficient mice]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E338</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E331</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E339?rss=1">
<title><![CDATA[Induction of stearoyl-CoA desaturase protects human arterial endothelial cells against lipotoxicity]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E339?rss=1</link>
<description><![CDATA[ 
<P>Endothelial lipotoxicity has been implicated in the pathogenesis of multiple stages of cardiovascular disease from early endothelial dysfunction to manifest atherosclerosis and its complications. Saturated free fatty acids are the major inducers of endothelial cell apoptosis and inflammatory cytokines. In humans, the enzyme human stearoyl-CoA desaturase-1 (hSCD-1) is the limiting step of the desaturation of saturated to monounsaturated fatty acids. Since we could demonstrate the expression of SCD-1 in primary human arterial endothelial cells (HAECs), we aimed to prove a beneficial role of upregulated hSCD-1 expression. In contrast to other cells that are less susceptible to lipotoxicity, hSCD-1 was not upregulated in HAECs upon palmitate treatment. Following that, we could show that upregulation of hSCD-1 using the LXR activator TO-901317 in HAECs protects the cells against palmitate-induced lipotoxicity, cell apoptosis, and expression of inflammatory cytokines IL-6 and IL-8. Increased hSCD-1 activity was determined as increased C16:1/16:0 ratio and enhanced triglyceride storage in palmitate treated cells. The beneficial effect was clearly attributed to enhanced hSCD-1 activity. Overexpression of hSCD-1 blocked palmitate-induced cytotoxicity, and knockdown of hSCD-1 using siRNA abolished the protective effect of TO-901317 in HEK-293 cells. Additionally, inhibition of hSCD-1 with 10/12 CLA blocked the effect of TO-901317 on palmitate-induced lipotoxicity, cell apoptosis, and inflammatory cytokine induction in HAECs. We conclude that upregulation of hSCD-1 leads to a desaturation of saturated fatty acids and facilitates their esterification and storage, thereby preventing downstream effects of lipotoxicity in HAECs. These findings add a novel aspect to the atheroprotective actions of LXR activators in cardiovascular disease.</P>
]]></description>
<dc:creator><![CDATA[Peter, A., Weigert, C., Staiger, H., Rittig, K., Cegan, A., Lutz, P., Machicao, F., Haring, H.-U., Schleicher, E.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00022.2008</dc:identifier>
<dc:title><![CDATA[Induction of stearoyl-CoA desaturase protects human arterial endothelial cells against lipotoxicity]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E349</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E339</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E350?rss=1">
<title><![CDATA[Deficiency of glucose-dependent insulinotropic polypeptide receptor prevents ovariectomy-induced obesity in mice]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E350?rss=1</link>
<description><![CDATA[ 
<P>Menopause and premature gonadal steroid deficiency are associated with increases in fat mass and body weight. Ovariectomized (OVX) mice also show reduced locomotor activity. Glucose-dependent-insulinotropic-polypeptide (GIP) is known to play an important role both in fat metabolism and locomotor activity. Therefore, we hypothesized that the effects of estrogen on the regulation of body weight, fat mass, and spontaneous physical activity could be mediated in part by GIP signaling. To test this hypothesis, C57BL/6 mice and GIP-receptor knockout mice (Gipr<SUP>&ndash;/&ndash;</SUP>) were exposed to OVX or sham operation (<I>n</I> = 10 per group). The effects on body composition, markers of insulin resistance, energy expenditure, locomotor activity, and expression of hypothalamic anorexigenic and orexigenic factors were investigated over 26 wk in all four groups of mice. OVX wild-type mice developed obesity, increased fat mass, and elevated markers of insulin resistance as expected. This was completely prevented in OVX Gipr<SUP>&ndash;/&ndash;</SUP> animals, even though their energy expenditure and spontaneous locomotor activity levels did not significantly differ from those of OVX wild-type mice. Cumulative food intake in OVX Gipr<SUP>&ndash;/&ndash;</SUP> animals was significantly reduced and associated with significantly lower hypothalamic mRNA expression of the orexigenic neuropeptide Y (NPY) but not of cocaine-amphetamine-related transcript (CART), melanocortin receptors (MCR-3 and MCR-4), or thyrotropin-releasing hormone (TRH). GIP receptors thus interact with estrogens in the hypothalamic regulation of food intake in mice, and their blockade may carry promising potential for the prevention of obesity in gonadal steroid deficiency.</P>
]]></description>
<dc:creator><![CDATA[Isken, F., Pfeiffer, A. F. H., Nogueiras, R., Osterhoff, M. A., Ristow, M., Thorens, B., Tschop, M. H., Weickert, M. O.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00008.2008</dc:identifier>
<dc:title><![CDATA[Deficiency of glucose-dependent insulinotropic polypeptide receptor prevents ovariectomy-induced obesity in mice]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E355</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E350</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E356?rss=1">
<title><![CDATA[Induction of muscle thermogenesis by high-fat diet in mice: association with obesity-resistance]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E356?rss=1</link>
<description><![CDATA[ 
<P>The obesogenic effect of a high-fat (HF) diet is counterbalanced by stimulation of energy expenditure and lipid oxidation in response to a meal. The aim of this study was to reveal whether muscle nonshivering thermogenesis could be stimulated by a HF diet, especially in obesity-resistant A/J compared with obesity-prone C57BL/6J (B/6J) mice. Experiments were performed on male mice born and maintained at 30&deg;C. Four-week-old mice were randomly weaned onto a low-fat (LF) or HF diet for 2 wk. In the A/J LF mice, cold exposure (4&deg;C) resulted in hypothermia, whereas the A/J HF, B/6J LF, and B/6J HF mice were cold tolerant. Cold sensitivity of the A/J LF mice was associated with a relatively low whole body energy expenditure under resting conditions, which was normalized by the HF diet. In both strains, the HF diet induced uncoupling protein-1-mediated thermogenesis, with a stronger induction in A/J mice. Only in A/J mice: <I>1</I>) the HF diet augmented activation of whole body lipid oxidation by cold; and <I>2</I>) at 30&deg;C, oxygen consumption, total content, and phosphorylation of AMP-activated protein kinase (AMPK), and AICAR-stimulated palmitate oxidation in soleus muscle was increased by the HF diet in parallel with significantly increased leptinemia. Gene expression data in soleus muscle of the A/J HF mice indicated a shift from carbohydrate to fatty acid oxidation. Our results suggest a role for muscle nonshivering thermogenesis and lipid oxidation in the obesity-resistant phenotype of A/J mice and indicate that a HF diet could induce thermogenesis in oxidative muscle, possibly via the leptin-AMPK axis.</P>
]]></description>
<dc:creator><![CDATA[Kus, V., Prazak, T., Brauner, P., Hensler, M., Kuda, O., Flachs, P., Janovska, P., Medrikova, D., Rossmeisl, M., Jilkova, Z., Stefl, B., Pastalkova, E., Drahota, Z., Houstek, J., Kopecky, J.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90256.2008</dc:identifier>
<dc:title><![CDATA[Induction of muscle thermogenesis by high-fat diet in mice: association with obesity-resistance]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E367</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E356</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E368?rss=1">
<title><![CDATA[Sodium arsenite induces orphan nuclear receptor SHP gene expression via AMP-activated protein kinase to inhibit gluconeogenic enzyme gene expression]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E368?rss=1</link>
<description><![CDATA[ 
<P>Sodium arsenite has been demonstrated to alter the expression of genes associated with glucose homeostasis in tissues involved in the pathogenesis of type 2 diabetes; however, the underlying molecular mechanism has not been fully elucidated yet. In this study, we report that the sodium arsenite-induced gene expression of the small heterodimer partner (SHP; NR0B2), an atypical orphan nuclear receptor, regulates the expression of hepatic gluconeogenic genes. Sodium arsenite augments hepatic SHP mRNA levels in an AMP-activated protein kinase (AMPK)-dependent manner. Sodium arsenite activated AMPK and was shown to perturb cellular ATP levels. The arsenite-induced SHP mRNA level was blocked by adenoviral overexpression of dominant negative AMPK (Ad-dnAMPK) or by the AMPK inhibitor compound C in hepatic cell lines. We demonstrated the dose-dependent induction of SHP mRNA levels by sodium arsenite and repressed the forskolin/dexamethasone-induced gene expression of the key hepatic gluconeogenic genes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). Ad-dnAMPK blocked the repressive effects of arsenite-induced SHP on PEPCK and G6Pase. Sodium arsenite inhibited the promoter activity of PEPCK and G6Pase, and this repression was abolished by small interfering (si)RNA SHP treatments. The knockdown of SHP expression by oligonucleotide siRNA SHP or adenoviral siRNA SHP released the sodium arsenite-mediated repression of forskolin/dexamethasone-stimulated PEPCK and G6Pase gene expression in a variety of hepatic cell lines. Results from our study suggest that sodium arsenite induces SHP via AMPK to inhibit the expression of hepatic gluconeogenic genes and also provide us with a novel molecular mechanism of arsenite-mediated regulation of hepatic glucose homeostasis.</P>
]]></description>
<dc:creator><![CDATA[Chanda, D., Kim, S.-J., Lee, I.-K., Shong, M., Choi, H.-S.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00800.2007</dc:identifier>
<dc:title><![CDATA[Sodium arsenite induces orphan nuclear receptor SHP gene expression via AMP-activated protein kinase to inhibit gluconeogenic enzyme gene expression]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E379</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E368</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E380?rss=1">
<title><![CDATA[Effect of continuous positive airway pressure therapy on hypothalamic-pituitary-adrenal axis function and 24-h blood pressure profile in obese men with obstructive sleep apnea syndrome]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E380?rss=1</link>
<description><![CDATA[ 
<P>Obstructive sleep apnea syndrome (OSAS) increases the risk of cardiovascular events. Sympathetic nervous system and hypothalamic-pituitary-adrenal (HPA) axis activation may be the mechanism of this relationship. The aim of this study was to evaluate HPA axis and ambulatory blood pressure monitoring in obese men with and without OSAS and to determine whether nasal continuous positive airway pressure therapy (nCPAP) influenced responses. Twenty-four-hour ambulatory blood pressure monitoring and overnight cortisol suppression test with 0.25 mg of dexamethasone were performed in 16 obese men with OSAS and 13 obese men controls. Nine men with severe apnea were reevaluated 3 mo after nCPAP therapy. Body mass index and blood pressure of OSAS patients and obese controls were similar. In OSAS patients, the percentage of fall in systolic blood pressure at night (<I>P</I> = 0.027) and salivary cortisol suppression postdexamethasone (<I>P</I> = 0.038) were lower, whereas heart rate (<I>P</I> = 0.022) was higher compared with obese controls. After nCPAP therapy, patients showed a reduction in heart rate (<I>P</I> = 0.036) and a greater cortisol suppression after dexamethasone (<I>P</I> = 0.001). No difference in arterial blood pressure (<I>P</I> = 0.183) was observed after 3 mo of nCPAP therapy. Improvement in cortisol suppression was positively correlated with an improvement in apnea-hypopnea index during nCPAP therapy (<I>r</I> = 0.799, <I>P</I> = 0.010). In conclusion, men with OSAS present increased postdexamethasone cortisol levels and heart rate, which were recovered by nCPAP.</P>
]]></description>
<dc:creator><![CDATA[Carneiro, G., Togeiro, S. M., Hayashi, L. F., Ribeiro-Filho, F. F., Ribeiro, A. B., Tufik, S., Zanella, M. T.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00780.2007</dc:identifier>
<dc:title><![CDATA[Effect of continuous positive airway pressure therapy on hypothalamic-pituitary-adrenal axis function and 24-h blood pressure profile in obese men with obstructive sleep apnea syndrome]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E384</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E380</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E385?rss=1">
<title><![CDATA[Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E385?rss=1</link>
<description><![CDATA[ 
<P>Although body composition, insulin sensitivity, and lipids are markedly altered in overweight adolescents, hormonal associations with these parameters have not been well characterized. Growth hormone (GH) deficiency and hypercortisolemia predispose to abdominal adiposity and insulin resistance, and GH secretion is decreased in obese adults. We hypothesized that low-peak GH on the GH-releasing hormone (GHRH)-arginine stimulation test and high cortisol in overweight adolescents would be associated with higher regional fat, insulin resistance, and lipids. We examined the following parameters in 15 overweight and 15 bone age-matched control 12- to 18-yr-old girls: <I>1</I>) body composition using dual-energy X-ray absorptiometry and MR [visceral and subcutaneous adipose tissue at L<SUB>4</SUB>&ndash;L<SUB>5</SUB> and soleus intramyocellular lipid (<SUP>1</SUP>H-MR spectroscopy)], <I>2</I>) peak GH on the GHRH-arginine stimulation test, <I>3</I>) mean overnight GH and cortisol, <I>4</I>) 24-h urinary free cortisol (UFC), <I>5</I>) fasting lipids, and <I>6</I>) an oral glucose tolerance test. Stepwise regression was the major tool employed to determine relationships between measured parameters. Log peak GH on the GHRH-arginine test was lower (<I>P</I> = 0.03) and log UFC was higher (<I>P</I> = 0.02) in overweight girls. Log mean cortisol (overnight sampling) was associated positively with subcutaneous adipose tissue and, with body mass index standard deviation score, accounted for 92% of its variability, whereas log peak GH and body mass index standard deviation score accounted for 88% of visceral adipose tissue variability and log peak GH for 34% of the intramyocellular lipid variability. Log mean cortisol was independently associated with log homeostasis model assessment of insulin resistance, LDL, and HDL and explained 49&ndash;59% of the variability. Our data indicate that lower peak GH and higher UFC in overweight girls are associated with visceral adiposity, insulin resistance, and lipids.</P>
]]></description>
<dc:creator><![CDATA[Misra, M., Bredella, M. A., Tsai, P., Mendes, N., Miller, K. K., Klibanski, A.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.00052.2008</dc:identifier>
<dc:title><![CDATA[Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E392</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E385</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E393?rss=1">
<title><![CDATA[Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E393?rss=1</link>
<description><![CDATA[ 
<P>Obesity and elevated cytokine secretion result in a chronic inflammatory state and may cause the insulin resistance observed in type 2 diabetes. Recent studies suggest a key role for endoplasmic reticulum stress in hepatocytes and adipocytes from obese mice, resulting in reduced insulin sensitivity. To address the hypothesis that thiazolidinediones, which improve peripheral insulin sensitivity, act in part by reducing the endoplasmic reticulum stress response, we tested subcutaneous adipose tissue from 20 obese volunteers treated with pioglitazone for 10 wk. We also experimentally induced endoplasmic reticulum stress using palmitate, tunicamycin, and thapsigargin in the human HepG2 liver cell line with or without pioglitazone pretreatment. We quantified endoplasmic reticulum stress response by measuring both gene expression and phosphorylation. Pioglitazone significantly improved insulin sensitivity in human volunteers (<I>P</I> = 0.002) but did not alter markers of endoplasmic reticulum stress. Differences in pre- and posttreatment endoplasmic reticulum stress levels were not correlated with changes in insulin sensitivity or body mass index. In vitro, palmitate, thapsigargin, and tunicamycin but not oleate induced endoplasmic reticulum stress in HepG2 cells, including increased transcripts CHOP, ERN1, GADD34, and PERK, and increased XBP1 splicing along with phosphorylation of eukaryotic initiation factor eIF2, JNK1, and c-<I>jun</I>. Although patterns of endoplasmic reticulum stress response differed among palmitate, tunicamycin, and thapsigargin, pioglitazone pretreatment had no significant effect on any measure of endoplasmic reticulum stress, regardless of the inducer. Together, our data suggest that improved insulin sensitivity with pioglitazone is not mediated by a reduction in endoplasmic reticulum stress.</P>
]]></description>
<dc:creator><![CDATA[Das, S. K., Chu, W. S., Mondal, A. K., Sharma, N. K., Kern, P. A., Rasouli, N., Elbein, S. C.]]></dc:creator>
<dc:date>2008-08-01</dc:date>
<dc:identifier>info:doi/10.1152/ajpendo.90355.2008</dc:identifier>
<dc:title><![CDATA[Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines]]></dc:title>
<dc:publisher>American Physiological Society</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>295</prism:volume>
<prism:endingPage>E400</prism:endingPage>
<prism:publicationDate>2008-08-01</prism:publicationDate>
<prism:startingPage>E393</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://ajpendo.physiology.org/cgi/content/abstract/295/2/E401?rss=1">
<title><![CDATA[The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance]]></title>
<link>http://ajpendo.physiology.org/cgi/content/abstract/295/2/E401?rss=1</link>
<description><![CDATA[ 
<P>To assess the relationship between the fasting plasma glucose (FPG) concentration and insulin secretion in normal glucose tolerance (NGT) and impaired glucose tolerance (IGT) subjects, 531 nondiabetic subjects with NGT (<I>n</I> = 293) and IGT (<I>n</I> = 238; 310 Japanese and 232 Mexican Americans) received an oral glucose tolerance test (OGTT) with measurement of plasma glucose, insulin, and C-peptide every 30 min. The insulin secretion rate was determined by plasma C-peptide deconvolution. Insulin sensitivity (Matsuda index) was measured from plasma insulin and glucose concentrations. The insulin secretion/insulin resistance (IS/IR) or disposition index was calculated as ISR/G &divide; IR. As FPG increased in NGT subjects, the IS/IR index declined exponentially over the range of FPG from 70 to 125 mg/dl. The relationship between the IS/IR index and FPG was best fit with the equation: 28.8 exp(&ndash;0.036 FPG). For every 28 mg/dl increase in FPG, the IS/IR index declined by 63%. A similar relationship between IS/IR index and FPG was observed in IGT. However, the decay constant was lower than in NGT. The IS/IR index for early-phase insulin secretion (0&ndash;30 min) was correlated with the increase in FPG in both NGT and IGT (<I>r</I> = &ndash;0.43, <I>P</I> &lt; 0.0001 and <I>r</I> = &ndash;0.20, <I>P</I> = 0.001, respectively). However, the correlation between late-phase insulin secretion (60&ndash;120 min) and FPG was not significant. In conclusion, small increments in FPG, within 